About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
Biosimilars
Current news
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2013
06.11.2013
Reaction to agreement on terms of 2014 PPRS
09.10.2013
EGA Vision of Future for European Generic and Biosimilar Medicines
08.10.2013
Generics must not lose sight of core mission
04.10.2013
Nick Haggar to take over the Presidency of the EGA
02.09.2013
Adrian Van Den Hoven appointed as the new Director General of the EGA
20.05.2013
Medicines UK to Stage a Workshop on API Importation Requirements - supported by the MHRA
25.04.2013
NHS wasting hundreds of millions by not using biosimilars
11.02.2013
Medicines UK Current Industry Issues
Highlights
25.06.2020
Life Sciences Recovery Roadmap
16.06.2020
Reaction to dexamethasone treatment for Covid-19 patients
02.04.2020
Statement of intent for UK life sciences
25.03.2020
COVID-19 Medicines UK update
20.03.2020
Key worker welcome
18.03.2020
Covid-19 statement
04.03.2020
Response to today's CMA fines on anti-competitive agreements
06.02.2020
Reaction to the Government's document on the UK's approach to trade deals with non-EU nations